
## Francesco Dentali

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9190040/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Antithrombotic Therapy for VTE Disease. Chest, 2012, 141, e419S-e496S.	0.8	3,745
2	Prevention of VTE in Nonsurgical Patients. Chest, 2012, 141, e195S-e226S.	0.8	1,780
3	Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nature Reviews Immunology, 2021, 21, 319-329.	22.7	594
4	Meta-analysis: Anticoagulant Prophylaxis to Prevent Symptomatic Venous Thromboembolism in Hospitalized Medical Patients. Annals of Internal Medicine, 2007, 146, 278.	3.9	455
5	European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis – endorsed by the European Academy of Neurology. European Journal of Neurology, 2017, 24, 1203-1213.	3.3	434
6	Meta-Analysis: Low-Molecular-Weight Heparin and Bleeding in Patients with Severe Renal Insufficiency. Annals of Internal Medicine, 2006, 144, 673.	3.9	365
7	Efficacy and Safety of the Novel Oral Anticoagulants in Atrial Fibrillation. Circulation, 2012, 126, 2381-2391.	1.6	359
8	American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Advances, 2018, 2, 3257-3291.	5.2	328
9	Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. Thrombosis and Haemostasis, 2011, 106, 429-438.	3.4	295
10	Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis. Blood, 2006, 107, 2766-2773.	1.4	227
11	Natural history of cerebral vein thrombosis: a systematic review. Blood, 2006, 108, 1129-1134.	1.4	202
12	Risk of Thromboembolism, Recurrent Hemorrhage, and Death After Warfarin Therapy Interruption for Gastrointestinal Tract Bleeding. Archives of Internal Medicine, 2012, 172, 1484.	3.8	202
13	Non-O Blood Type Is the Commonest Genetic Risk Factor for VTE: Results from a Meta-Analysis of the Literature. Seminars in Thrombosis and Hemostasis, 2012, 38, 535-548.	2.7	195
14	Prevalence and Clinical History of Incidental, Asymptomatic Pulmonary Embolism: A Meta-Analysis. Thrombosis Research, 2010, 125, 518-522.	1.7	189
15	Neutrophils and clinical outcomes in patients with acute coronary syndromes and/or cardiac revascularisation. Thrombosis and Haemostasis, 2011, 106, 591-599.	3.4	185
16	Long-term Clinical Outcomes of Splanchnic Vein Thrombosis. JAMA Internal Medicine, 2015, 175, 1474.	5.1	180
17	Combined Aspirin–Oral Anticoagulant Therapy Compared With Oral Anticoagulant Therapy Alone Among Patients at Risk for Cardiovascular Disease. Archives of Internal Medicine, 2007, 167, 117.	3.8	172
18	JAK2V617F mutation for the early diagnosis of Phâ^' myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood, 2009, 113, 5617-5623.	1.4	162

#	Article	IF	CITATIONS
19	Mucosal immune response in BNT162b2 COVID-19 vaccine recipients. EBioMedicine, 2022, 75, 103788.	6.1	149
20	The metabolic syndrome and the risk of venous thrombosis: a case–control study. Journal of Thrombosis and Haemostasis, 2006, 4, 1914-1918.	3.8	144
21	European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis – Endorsed by the European Academy of Neurology. European Stroke Journal, 2017, 2, 195-221.	5.5	144
22	Incidence of chronic pulmonary hypertension in patients with previous pulmonary embolism. Thrombosis Research, 2009, 124, 256-258.	1.7	135
23	Longâ€ŧerm outcomes of patients with cerebral vein thrombosis: a multicenter study. Journal of Thrombosis and Haemostasis, 2012, 10, 1297-1302.	3.8	129
24	Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. Journal of Thrombosis and Haemostasis, 2006, 4, 1853-1863.	3.8	126
25	SARS-CoV-2: a potential trigger for subacute thyroiditis? Insights from a case report. Journal of Endocrinological Investigation, 2020, 43, 1171-1172.	3.3	116
26	Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis. Thrombosis and Haemostasis, 2014, 111, 172-179.	3.4	97
27	Dâ€dimer testing in the diagnosis of cerebral vein thrombosis: a systematic review and a metaâ€analysis of the literature. Journal of Thrombosis and Haemostasis, 2012, 10, 582-589.	3.8	94
28	Thrombosis prophylaxis in medical patients: a retrospective review of clinical practice patterns. Haematologica, 2002, 87, 746-50; discussion 250.	3.5	91
29	Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a metaâ€analysis of the literature. Journal of Thrombosis and Haemostasis, 2013, 11, 270-281.	3.8	88
30	Inherited thrombophilic abnormalities and risk of portal vein thrombosis. Thrombosis and Haemostasis, 2008, 99, 675-682.	3.4	86
31	Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy. Thrombosis and Haemostasis, 2016, 115, 399-405.	3.4	85
32	Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome. Thrombosis and Haemostasis, 2017, 117, 794-800.	3.4	85
33	Safety of thrombolysis in cerebral venous thrombosis. Thrombosis and Haemostasis, 2010, 104, 1055-1062.	3.4	82
34	Seasonal and monthly variability in the incidence of venous thromboembolism. Thrombosis and Haemostasis, 2011, 106, 439-447.	3.4	79
35	Natural anticoagulants deficiency and the risk of venous thromboembolism: a meta-analysis of observational studies. Thrombosis Research, 2015, 135, 923-932.	1.7	78
36	Prevalence of deep vein thrombosis and pulmonary embolism in patients with superficial vein thrombosis: a systematic review and metaâ€analysis. Journal of Thrombosis and Haemostasis, 2016, 14, 964-972.	3.8	78

#	Article	IF	CITATIONS
37	The impact of deep vein thrombosis in critically ill patients: a meta-analysis of major clinical outcomes. Blood Transfusion, 2015, 13, 559-68.	0.4	78
38	How I treat splanchnic vein thrombosis. Blood, 2014, 124, 3685-3691.	1.4	71
39	PM10 exposure is associated with increased hospitalizations for respiratory syncytial virus bronchiolitis among infants in Lombardy, Italy. Environmental Research, 2018, 166, 452-457.	7.5	70
40	Incidence of venous thromboembolism in patients undergoing thoracotomy for lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2008, 135, 705-706.	0.8	67
41	Relationship between ABO Blood Group and Hemorrhage: A Systematic Literature Review and Meta-Analysis. Seminars in Thrombosis and Hemostasis, 2013, 39, 072-082.	2.7	67
42	ABO Blood Group and Vascular Disease: An Update. Seminars in Thrombosis and Hemostasis, 2014, 40, 049-059.	2.7	67
43	Impact of neutrophils to lymphocytes ratio on major clinical outcomes in patients with acute coronary syndromes: A systematic review and meta-analysis of the literature. International Journal of Cardiology, 2018, 266, 31-37.	1.7	67
44	Rapid Salivary Test suitable for a mass screening program to detect SARS-CoV-2: A diagnostic accuracy study. Journal of Infection, 2020, 81, e75-e78.	3.3	67
45	Prognostic relevance of an asymptomatic venous thromboembolism in patients with cancer. Journal of Thrombosis and Haemostasis, 2011, 9, 1081-1083.	3.8	63
46	Duration of anticoagulation after venous thromboembolism in real world clinical practice. Thrombosis Research, 2015, 135, 666-672.	1.7	62
47	The role of IL-6 and IL-6 blockade in COVID-19. Expert Review of Clinical Immunology, 2021, 17, 601-618.	3.0	62
48	Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens. Thrombosis and Haemostasis, 2017, 117, 382-389.	3.4	59
49	Natural history of mesenteric venous thrombosis in patients treated with vitamin K antagonists. Thrombosis and Haemostasis, 2009, 102, 501-504.	3.4	58
50	Management of anticoagulation in patients with acute gastrointestinal bleeding. Digestive and Liver Disease, 2015, 47, 621-627.	0.9	58
51	The Metabolic Syndrome as a Risk Factor for Venous and Arterial Thrombosis. Seminars in Thrombosis and Hemostasis, 2009, 35, 451-457.	2.7	57
52	Long-Term Outcome of Splanchnic Vein Thrombosis in Cirrhosis. Clinical and Translational Gastroenterology, 2018, 9, e176.	2.5	57
53	Chronobiology of acute aortic rupture or dissection: A systematic review and a meta-analysis of the literature. Chronobiology International, 2015, 32, 385-394.	2.0	55
54	Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry. Lancet Haematology,the, 2016, 3, e267-e275.	4.6	55

#	Article	IF	CITATIONS
55	External validation of the DASH prediction rule: a retrospective cohort study. Journal of Thrombosis and Haemostasis, 2017, 15, 1963-1970.	3.8	55
56	Clinical approach to splanchnic vein thrombosis: Risk factors and treatment. Thrombosis Research, 2012, 130, S1-S3.	1.7	54
57	Prognostic clinical prediction rules to identify a lowâ€risk pulmonary embolism: a systematic review and metaâ€analysis. Journal of Thrombosis and Haemostasis, 2012, 10, 1276-1290.	3.8	53
58	Survival and recurrent venous thromboembolism in patients with first proximal or isolated distal deep vein thrombosis and no pulmonary embolism. Journal of Thrombosis and Haemostasis, 2017, 15, 1436-1442.	3.8	53
59	SARS-CoV-2 on Ocular Surfaces in a Cohort of Patients With COVID-19 From the Lombardy Region, Italy. JAMA Ophthalmology, 2021, 139, 956.	2.5	52
60	Association between inherited thrombophilic abnormalities and central venous catheter thrombosis in patients with cancer: a meta-analysis. Journal of Thrombosis and Haemostasis, 2007, 6, 70-75.	3.8	51
61	Incidental diagnosis of a deep vein thrombosis in consecutive patients undergoing a computed tomography scan of the abdomen: a retrospective cohort study. Journal of Thrombosis and Haemostasis, 2012, 10, 158-160.	3.8	49
62	Association Between the Metabolic Syndrome, Its Individual Components, and Unprovoked Venous Thromboembolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 2478-2485.	2.4	48
63	Cerebral venous thrombosis and myeloproliferative neoplasms: Results from two large databases. Thrombosis Research, 2014, 134, 41-43.	1.7	47
64	The role of thrombolytic therapy in pulmonary embolism. Blood, 2015, 125, 2191-2199.	1.4	47
65	Brand Name versus Generic Warfarin: A Systematic Review of the Literature. Pharmacotherapy, 2011, 31, 386-393.	2.6	46
66	Lowâ€dose aspirin for in vitro fertilization or intracytoplasmic sperm injection: a systematic review and a metaâ€analysis of the literature. Journal of Thrombosis and Haemostasis, 2012, 10, 2075-2085.	3.8	45
67	Warfarin Interactions With Antibiotics in the Ambulatory Care Setting. JAMA Internal Medicine, 2014, 174, 409.	5.1	44
68	Italian intersociety consensus on DOAC use in internal medicine. Internal and Emergency Medicine, 2017, 12, 387-406.	2.0	44
69	Pulmonary embolism severity index accurately predicts longâ€ŧerm mortality rate in patients hospitalized for acute pulmonary embolism. Journal of Thrombosis and Haemostasis, 2013, 11, 2103-2110.	3.8	42
70	Antithrombotic Treatment of Splanchnic Vein Thrombosis: Results of an International Registry. Seminars in Thrombosis and Hemostasis, 2014, 40, 099-105.	2.7	39
71	Clinical course of isolated distal deep vein thrombosis in patients with active cancer: a multicenter cohort study. Journal of Thrombosis and Haemostasis, 2017, 15, 1757-1763.	3.8	38
72	Patients with isolated pulmonary embolism in comparison to those with deep venous thrombosis. Differences in characteristics and clinical evolution. European Journal of Internal Medicine, 2019, 69, 64-70.	2.2	34

#	Article	IF	CITATIONS
73	Rate and duration of hospitalization for deep vein thrombosis and pulmonary embolism in real-world clinical practice. Annals of Medicine, 2015, 47, 546-554.	3.8	33
74	In-hospital mortality for pulmonary embolism: relationship with chronic kidney disease and end-stage renal disease. The hospital admission and discharge database of the Emilia Romagna region of Italy. Internal and Emergency Medicine, 2013, 8, 735-740.	2.0	30
75	Ferritin as prognostic marker in COVID-19: the FerVid study. Postgraduate Medicine, 2021, , 1-6.	2.0	30
76	Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for intracranial hemorrhage. Thrombosis Research, 2015, 136, 1040-1044.	1.7	29
77	Periendoscopic management of direct oral anticoagulants: a prospective cohort study. Gut, 2019, 68, 969-976.	12.1	28
78	Use of statins and recurrence of atrial fibrillation after catheter ablation or electrical cardioversion. Thrombosis and Haemostasis, 2011, 106, 363-370.	3.4	27
79	Association Between In-Hospital Mortality and Renal Dysfunction in 186 219 Patients Hospitalized for Acute Stroke in the Emilia-Romagna Region of Italy. Angiology, 2014, 65, 906-910.	1.8	27
80	Long-term recurrence of venous thromboembolism after short-term treatment of symptomatic isolated distal deep vein thrombosis: A cohort study. Vascular Medicine, 2017, 22, 518-524.	1.5	27
81	Prognostic role of neutrophils to lymphocytes ratio in patients with acute pulmonary embolism: a systematic review and meta-analysis of the literature. Internal and Emergency Medicine, 2018, 13, 603-608.	2.0	26
82	Intracranial bleeding risk after minor traumatic brain injury in patients on antithrombotic drugs. Thrombosis Research, 2019, 174, 113-120.	1.7	26
83	Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism. Internal and Emergency Medicine, 2009, 4, 123-128.	2.0	25
84	Incidence of thromboembolic complications in patients with atrial fibrillation or mechanical heart valves with a subtherapeutic international normalized ratio: A prospective multicenter cohort study. American Journal of Hematology, 2012, 87, 384-387.	4.1	25
85	Dural Arteriovenous Fistulae After Cerebral Venous Thrombosis. Stroke, 2020, 51, 3344-3347.	2.0	25
86	Efficacy of low molecular weight heparin in patients undergoing inÂvitro fertilization or intracytoplasmic sperm injection. Journal of Thrombosis and Haemostasis, 2011, 9, 2503-2506.	3.8	24
87	Pregnancy-related venous thrombosis: comparison between spontaneous and ART conception in an Italian cohort. BMJ Open, 2015, 5, e008213.	1.9	24
88	The prevention and treatment of venous thromboembolism in pregnancy. Expert Review of Cardiovascular Therapy, 2017, 15, 397-402.	1.5	24
89	Efficacy and safety of extended thromboprophylaxis for medically ill patients. Thrombosis and Haemostasis, 2017, 117, 606-617.	3.4	24
90	DVT Management andÂOutcome Trends, 2001 to 2014. Chest, 2016, 150, 374-383.	0.8	23

#	Article	IF	CITATIONS
91	Role of factorÂV Leiden or G20210A prothrombin mutation in patients with symptomatic pulmonary embolism and deep vein thrombosis: a metaâ€analysis of the literature. Journal of Thrombosis and Haemostasis, 2012, 10, 732-737.	3.8	22
92	Safety and efficacy of lowâ€dose fondaparinux (1.5 mg) for the prevention of venous thromboembolism in acutely ill medical patients with renal impairment: the FONDAIR study. Journal of Thrombosis and Haemostasis, 2012, 10, 2291-2297.	3.8	21
93	Outcome during and after anticoagulant therapy in cancer patients with incidentally found pulmonary embolism. European Respiratory Journal, 2016, 48, 1360-1368.	6.7	21
94	Relationship between regulatory T cells subsets and lipid profile in dyslipidemic patients: a longitudinal study during atorvastatin treatment. BMC Cardiovascular Disorders, 2016, 16, 26.	1.7	21
95	Seasonal variability of venous thromboembolism. Current Opinion in Pulmonary Medicine, 2009, 15, 403-407.	2.6	20
96	Cerebral vein thrombosis. Internal and Emergency Medicine, 2010, 5, 27-32.	2.0	20
97	Non-vitamin K oral anticoagulants in patients with pulmonary embolism: a systematic review and meta-analysis of the literature. Internal and Emergency Medicine, 2015, 10, 507-514.	2.0	20
98	Splanchnic vein thrombosis: new risk factors and management. Thrombosis Research, 2012, 129, S93-S96.	1.7	19
99	Carotid atherosclerosis and risk for ischemic stroke in patients with atrial fibrillation on oral anticoagulant treatment. Atherosclerosis, 2018, 271, 177-181.	0.8	19
100	The effect of recanalization on longâ€ŧerm neurological outcome after cerebral venous thrombosis. Journal of Thrombosis and Haemostasis, 2018, 16, 718-724.	3.8	19
101	Emergency reversal of anticoagulation with vitamin K antagonists with 3-factor prothrombin complex concentrates in patients with major bleeding. Journal of Thrombosis and Thrombolysis, 2013, 36, 102-108.	2.1	18
102	Major Bleeding and Case Fatality Rate with the Direct Oral Anticoagulants in Orthopedic Surgery: A Systematic Review and Meta-Analysis. Seminars in Thrombosis and Hemostasis, 2016, 42, 042-054.	2.7	18
103	Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study. Journal of Thrombosis and Haemostasis, 2021, 19, 2751-2759.	3.8	18
104	Prevalence of renal failure and use of antithrombotic prophylaxis among medical inpatients at increased risk of venous thromboembolic events. Thrombosis Research, 2008, 123, 67-71.	1.7	17
105	Incidence of thromboembolic complications in patients with mechanical heart valves with a subtherapeutic international normalized ratio. Journal of Thoracic and Cardiovascular Surgery, 2009, 137, 91-93.	0.8	17
106	Evidence and clinical judgment: Treatment of cerebral vein thrombosis. Thrombosis and Haemostasis, 2010, 103, 1109-1115.	3.4	17
107	Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria phenotype in patients with splanchnic vein thrombosis. Thrombosis Research, 2014, 133, 1052-1055.	1.7	17
108	Unsuspected pulmonary embolism in cancer patients: a narrative review with pooled data. Internal and Emergency Medicine, 2014, 9, 375-384.	2.0	17

#	Article	IF	CITATIONS
109	Efficacy and safety of direct oral anticoagulants in patients undergoing cardioversion for atrial fibrillation: A systematic review and meta-analysis of the literature. International Journal of Cardiology, 2015, 185, 72-77.	1.7	17
110	Does Celecoxib Potentiate the Anticoagulant Effect of Warfarin? A Randomized, Double-Blind, Controlled Trial. Annals of Pharmacotherapy, 2006, 40, 1241-1247.	1.9	16
111	Natural history of cerebral vein thrombosis. Current Opinion in Pulmonary Medicine, 2007, 13, 372-376.	2.6	16
112	Optimal treatment duration of venous thrombosis. Journal of Thrombosis and Haemostasis, 2013, 11, 151-160.	3.8	16
113	Direct oral anticoagulants for the treatment of acute venous thromboembolism in patients with cancer: a meta-analysis of randomised controlled trials. European Respiratory Journal, 2017, 50, 1701097.	6.7	15
114	Management of coumarin-associated coagulopathy in the non-bleeding patient: a systematic review. Haematologica, 2004, 89, 857-62.	3.5	15
115	Prevalence and risk factors for pulmonary embolism in patients with suspected acute exacerbation of COPD: a multi-center study European Journal of Internal Medicine, 2020, 80, 54-59.	2.2	14
116	Clinical course of patients with symptomatic isolated superficial vein thrombosis: the ICARO followâ€up study. Journal of Thrombosis and Haemostasis, 2017, 15, 2176-2183.	3.8	13
117	Rate and duration of hospitalisation for acute pulmonary embolism in the real-world clinical practice of different countries: analysis from the RIETE registry. European Respiratory Journal, 2019, 53, 1801677.	6.7	13
118	Interleukin-1 and the NLRP3 Inflammasome in Pericardial Disease. Current Cardiology Reports, 2021, 23, 157.	2.9	13
119	In vitro effects of Apixaban on 5 different cancer cell lines. PLoS ONE, 2017, 12, e0185035.	2.5	13
120	Thalassemia trait and arterial thromboembolic events: a systematic review and a metaâ€analysis of the literature. Journal of Thrombosis and Haemostasis, 2011, 9, 917-921.	3.8	12
121	Role of ABO blood group as a prognostic factor in patients with spontaneous intracerebral hemorrhage. Journal of Thrombosis and Haemostasis, 2013, 11, 187-189.	3.8	12
122	Role of ABO blood group and of other risk factors on the presence of residual vein obstruction after deep-vein thrombosis. Thrombosis Research, 2014, 134, 264-267.	1.7	12
123	The role of inherited thrombophilia in patients with isolated pulmonary embolism: A systematic review and a meta-analysis of the literature. Thrombosis Research, 2014, 134, 84-89.	1.7	12
124	Safety of warfarin in "high-risk―populations: A meta-analysis of randomized and controlled trials. Thrombosis Research, 2017, 150, 1-7.	1.7	12
125	Perioperative Safety and Efficacy of Different Anticoagulation Strategies WithÂDirect Oral Anticoagulants in Pulmonary Vein Isolation. JACC: Clinical Electrophysiology, 2018, 4, 794-806.	3.2	12
126	High-dose dexamethasone treatment for COVID-19 severe acute respiratory distress syndrome: a retrospective study. Internal and Emergency Medicine, 2021, 16, 1913-1919.	2.0	12

#	Article	IF	CITATIONS
127	Polymorphisms of the Z protein protease inhibitor and risk of venous thromboembolism: a metaâ€analysis. British Journal of Haematology, 2008, 143, 284-287.	2.5	11
128	Low-molecular –weight heparin in pregnancies after ART -A retrospective study Thrombosis Research, 2014, 134, 336-339.	1.7	11
129	Diagnostic accuracy of magnetic resonance imaging in patients with suspected pulmonary embolism: A bivariate meta-analysis. Thrombosis Research, 2017, 154, 64-72.	1.7	11
130	Pulmonary embolism prognostic factors and length of hospital stay: A cohort study. Thrombosis Research, 2017, 156, 155-159.	1.7	11
131	PCSK9 inhibitors for treating dyslipidemia in patients at different cardiovascular risk: a systematic review and a meta-analysis. Internal and Emergency Medicine, 2017, 12, 1043-1053.	2.0	11
132	Chronobiologic Aspects of Venous Thromboembolism. Heart Failure Clinics, 2017, 13, 691-696.	2.1	11
133	Anti-SARS-CoV-2 RBD IgG responses in convalescent versus naÃ⁻ve BNT162b2 vaccine recipients. Vaccine, 2021, 39, 2489-2490.	3.8	11
134	SARS oVâ€2 B.1.1.7 reinfection after previous COVIDâ€19 in two immunocompetent Italian patients. Journal of Medical Virology, 2021, 93, 5648-5649.	5.0	11
135	Multidisciplinary approach to the management of patients with pulmonary embolism and deep vein thrombosis: a consensus on diagnosis, traditional therapy and therapy with rivaroxaban. Internal and Emergency Medicine, 2018, 13, 1037-1049.	2.0	10
136	What gastroenterologists should know about direct oral anticoagulants. Digestive and Liver Disease, 2020, 52, 1115-1125.	0.9	10
137	In-hospital fatality and venous thromboembolism during the first and second COVID-19 waves at a center opting for standard-dose thromboprophylaxis. Thrombosis Research, 2021, 203, 82-84.	1.7	10
138	Acute cardiovascular events in patients with community acquired pneumonia: results from the observational prospective FADOI-ICECAP study. BMC Infectious Diseases, 2021, 21, 116.	2.9	10
139	Direct oral anticoagulants for the treatment of unprovoked venous thromboembolism: a meta-analysis of randomised controlled trials. Blood Transfusion, 2015, 13, 391-5.	0.4	10
140	Incidence and diagnosis of pulmonary embolism in Northern Italy: A population-based study. European Journal of Internal Medicine, 2013, 24, e77-e78.	2.2	9
141	Clinical Pregnancies and Live Births in women approaching ART: A follow-up analysis of 157 women after thrombophilia screening. Thrombosis Research, 2014, 133, 168-172.	1.7	9
142	Prostanoids for Critical Limb Ischemia: A Clinical Review and Consideration of Current Guideline Recommendations. Angiology, 2020, 71, 226-234.	1.8	9
143	Derivation and Validation of a Prediction Model for Venous Thromboembolism in Primary Care. Thrombosis and Haemostasis, 2020, 120, 692-701.	3.4	9
144	Incidence Rates and Case-Fatality Rates of Cerebral Vein Thrombosis: A Population-Based Study. Stroke, 2021, 52, 3578-3585.	2.0	9

#	Article	IF	CITATIONS
145	Is there a role for timely diagnosis and early anticoagulant treatment of portal vein thrombosis in patients with liver cirrhosis?. Internal and Emergency Medicine, 2008, 3, 195-196.	2.0	8
146	Venous and Arterial Thrombosis Associated with HIV Infection. Seminars in Thrombosis and Hemostasis, 2012, 38, 524-529.	2.7	8
147	Recurrent venous thromboembolism: a role for ABO blood group?. Thrombosis and Haemostasis, 2013, 110, 1110-1111.	3.4	8
148	A clinical score to rule out the concomitant presence of deep vein thrombosis in patients presenting with superficial vein thrombosis: The ICARO study. Thrombosis Research, 2015, 136, 938-942.	1.7	8
149	Early alert from the microbiology laboratory improves the outcome of elderly patients with Enterococcus spp. bloodstream infection: Results from a multicentre prospective study. Journal of Global Antimicrobial Resistance, 2019, 18, 139-144.	2.2	8
150	sRAGE and early signs of cardiac target organ damage in mild hypertensives. Cardiovascular Diabetology, 2019, 18, 17.	6.8	8
151	Location of venous thrombosis in patients with FVL or prothrombin G20210A mutations: Systematic review and meta-analysis. Thrombosis and Haemostasis, 2013, 110, 191-194.	3.4	7
152	Effect of Vitamin K Intake on the Stability of Treatment with Vitamin K Antagonists: A Systematic Review of the Literature. Seminars in Thrombosis and Hemostasis, 2016, 42, 671-681.	2.7	7
153	Dabigatran in nonvalvular atrial fibrillation. Journal of Cardiovascular Medicine, 2017, 18, 467-477.	1.5	7
154	Residual vein obstruction in patients diagnosed with acute isolated distal deep vein thrombosis associated with active cancer. Journal of Thrombosis and Thrombolysis, 2018, 46, 404-408.	2.1	7
155	Introduction of SARS-CoV-2 variant of concern 20h/501Y.V2 (B.1.351) from Malawi to Italy. Emerging Microbes and Infections, 2021, 10, 710-712.	6.5	7
156	Winter and venous thromboembolism: a dangerous liaison?. Future Cardiology, 2011, 7, 717-719.	1.2	6
157	Prevalence of arterial and venous thromboembolic events in diabetic patients with and without the metabolic syndrome: A cross sectional study. Thrombosis Research, 2011, 127, 299-302.	1.7	6
158	Clinical Utility of Antithrombotic Prophylaxis in ART Procedures: An Italian Experience. PLoS ONE, 2014, 9, e97604.	2.5	6
159	Conservative Management of Intentional Massive Dabigatran Overdose. Journal of the American Geriatrics Society, 2015, 63, 2205-2207.	2.6	6
160	Portal Vein Thrombosis in Decompensated Cirrhosis: Rationale for Treatment. Clinical and Translational Gastroenterology, 2019, 10, e00026.	2.5	6
161	Advances in pharmacotherapy for acute and recurrent pericarditis. Expert Opinion on Pharmacotherapy, 2022, 23, 681-691.	1.8	6
162	Retrievable vena cava filters: clinical experience. Current Opinion in Internal Medicine, 2006, 5, 617-622.	1.5	5

#	Article	IF	CITATIONS
163	Statins for Acute Ischemic Stroke. Stroke, 2012, 43, .	2.0	5
164	Thromboprophylaxis in Acutely III Medical Patients: Results of A Survey Among Italian Physicians. Thrombosis Research, 2014, 134, 572-577.	1.7	5
165	Prevention and treatment of venous thromboembolism in patients with solid brain neoplasms: results of a survey among Italian physicians. Internal and Emergency Medicine, 2017, 12, 437-443.	2.0	5
166	Three-month mortality in permanently bedridden medical non-oncologic patients. The BECLAP study (permanently BEdridden, creatinine CLearance, albumin, previous hospital admissions study). European Journal of Internal Medicine, 2020, 72, 60-66.	2.2	5
167	PCSK9 as a new player in cancer: New opportunity or red herring?. Current Medicinal Chemistry, 2021, 28, .	2.4	5
168	Novel Risk Factors for Venous Thromboembolism. Hematology/Oncology Clinics of North America, 2010, 24, 709-716.	2.2	4
169	Evaluation of right ventricular function in patients with a previous episode of pulmonary embolism using tissue Doppler imaging. Internal and Emergency Medicine, 2013, 8, 689-694.	2.0	4
170	Are direct oral anticoagulants equally effective in reducing deep vein thrombosis and pulmonary embolism?. International Journal of Cardiology, 2015, 187, 645-647.	1.7	4
171	Efficacy and safety of extended antithrombotic prophylaxis in elderly medically ill patients. European Respiratory Journal, 2017, 49, 1601887.	6.7	4
172	Prophylaxis of Venous Thromboembolism after Hospital Discharge in Internal Medicine: Findings from the Observational FADOI-NoTEVole Study. Thrombosis and Haemostasis, 2019, 119, 2043-2052.	3.4	4
173	Risk of recurrence of unusual site venous thromboembolism. Hamostaseologie, 2013, 33, 225-231.	1.9	4
174	VTE recurrence in patients with inherited deficiencies of natural anticoagulants. Thrombosis and Haemostasis, 2009, 101, 5-6.	3.4	4
175	Prognostic stratification of chronic heart failure in elderly population: are cardiopulmonary tests and BNP really valuable?. Internal and Emergency Medicine, 2009, 4, 353-354.	2.0	3
176	Seasonal and monthly variation in occurrence of hypertensive urgency. Internal and Emergency Medicine, 2013, 8, 269-271.	2.0	3
177	Short-term prognosis of intracranial haemorrhage in patients on oral anticoagulant or antiplatelet drugs. Thrombosis Research, 2013, 132, 765-769.	1.7	3
178	Statin use and bleeding risk during vitamin K antagonist treatment for venous thromboembolism: a multicenter retrospective cohort study. Haematologica, 2015, 100, e295-8.	3.5	3
179	The safety of fondaparinux sodium for the treatment of venous thromboembolism. Expert Opinion on Drug Safety, 2016, 15, 1259-1265.	2.4	3
180	Is it reasonable to use a lower DOAC dose in some patients with VTE? NO. Internal and Emergency Medicine, 2017, 12, 565-567.	2.0	3

#	Article	lF	CITATIONS
181	The continuous challenge of antithrombotic strategies in diabetes: focus on direct oral anticoagulants. Acta Diabetologica, 2019, 56, 1247-1258.	2.5	3
182	Antiphospholipid Syndrome During Septic Shock: Hyper- or Hypocoagulability?: A Case Report. A&A Practice, 2019, 13, 306-309.	0.4	3
183	Sex-related characteristics of cerebral vein thrombosis: A secondary analysis of a multicenter international cohort study. Thrombosis Research, 2020, 196, 371-374.	1.7	3
184	>Acquired Factor XIII Deficiency Inducing Recurrent and Fatal Bleeding, Description of a Case. Journal of Blood Medicine, 2020, Volume 11, 43-45.	1.7	3
185	Neutrophil-to-lymphocyte ratio: a new prognostic factor even in patients with heart failure. Polish Archives of Internal Medicine, 2016, 126, 116-117.	0.4	3
186	Efficacy and safety of patent foramen ovale closure in patients with a cryptogenic stroke: Systematic review and meta-analysis. Thrombosis and Haemostasis, 2014, 111, 773-776.	3.4	2
187	Risk factors for suboptimal efficacy of 3-factor prothrombin complex concentrates in emergency VKA anticoagulation reversal. Thrombosis and Haemostasis, 2014, 112, 621-623.	3.4	2
188	In-hospital mortality due to pulmonary embolism in patients with Alzheimer disease: a sex effect?. American Journal of Emergency Medicine, 2016, 34, 665-666.	1.6	2
189	Argatroban for Treatment of Heparinâ€Induced Thrombocytopenia and Thrombosis in a Patient with Multiple Myeloma Undergoing Hemodialysis. Journal of the American Geriatrics Society, 2016, 64, 1748-1750.	2.6	2
190	Direct oral anticoagulants for superficial-vein thrombosis. Lancet Haematology,the, 2017, 4, e95-e96.	4.6	2
191	Brain natriuretic peptide and preclinical chronic thromboembolic pulmonary hypertension. Internal and Emergency Medicine, 2009, 4, 441-442.	2.0	1
192	Unmet clinical needs in the management of patients with splanchnic vein thrombosis. Internal and Emergency Medicine, 2010, 5, 459-461.	2.0	1
193	Mortality due to pulmonary embolism, myocardial infarction, and stroke among incident dialysis patients: a rebuttal. Journal of Thrombosis and Haemostasis, 2013, 11, 1207-1208.	3.8	1
194	The association between neonatal ABO blood group and intraventricular hemorrhage in extremely low birth weight infants: a reply to a comment. Journal of Thrombosis and Haemostasis, 2013, 11, 2075-2076.	3.8	1
195	Vitamin K antagonists in the era of direct oral anticoagulants: is there still a room for their use?. Internal and Emergency Medicine, 2017, 12, 1087-1089.	2.0	1
196	Inferior vena cava filter in patients with venous thromboembolism and major bleeding events: building the evidence. Internal and Emergency Medicine, 2019, 14, 1019-1020.	2.0	1
197	Vena Cava Filters and In-Hospital Case Fatality Among Patients With Pulmonary Embolism: Results From a Large Population-Based Study. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961988802.	1.7	1
198	Does Thromboprophylaxis Reduce Mortality in Medical Patients? A Systematic Review and Meta-Analysis of Randomized Cntrolled Tials Blood, 2005, 106, 905-905.	1.4	1

#	Article	IF	CITATIONS
199	Low Molecular Weight Heparin and Bleeding in Patients with Severe Renal Failure: A Meta-Analysis Blood, 2005, 106, 907-907.	1.4	1
200	Analysis Of Warfarin Drug-Drug Interactions With Antibiotics In The Ambulatory Care Setting. Blood, 2013, 122, 1143-1143.	1.4	1
201	Pulmonary embolism severity index accurately predicts long-term mortality rate in patients hospitalized for acute pulmonary embolism. European Heart Journal, 2013, 34, 760-760.	2.2	0
202	"To treat or not to treat very elderly naÃ⁻ve patients with atrial fibrillation with vitamin K antagonists― Internal and Emergency Medicine, 2015, 10, 765-767.	2.0	0
203	Progesterone Levels in Men with Unprovoked Deep Vein Thrombosis. Journal of the American Geriatrics Society, 2016, 64, 213-215.	2.6	0
204	Reply to "When to resume anticoagulation after acute gastrointestinal bleeding?― Digestive and Liver Disease, 2016, 48, 690-691.	0.9	0
205	Efficacy of thromboprophylaxis during pregnancy in women with a previous cerebral vein thrombosis. Internal and Emergency Medicine, 2017, 12, 913-914.	2.0	0
206	Direct oral anticoagulants in factor VII deficiency patient. Internal and Emergency Medicine, 2019, 14, 1353-1356.	2.0	0
207	D-dimer testing to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: follow the rules!. Internal and Emergency Medicine, 2020, 15, 369-370.	2.0	0
208	One score fits all: not always!. Internal and Emergency Medicine, 2020, 15, 919-920.	2.0	0
209	Management of antithrombotic therapy in gray areas of venous thromboembolism: a Delphi consensus panel. Internal and Emergency Medicine, 2020, 15, 1255-1264.	2.0	0
210	Comment on lowâ€dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatmentâ€free remission in chronic myeloid leukemia patients: Results of a retrospective study. Cancer, 2021, 127, 976-976.	4.1	0
211	Should High-Risk Patients with Chronic Atrial Fibrillation and Those with Coronary Artery Disease Receive Combined Aspirin-Oral Anticoagulant Therapy or Oral Anticoagulant Therapy Alone? A Systematic Review and Meta-Analysis Blood, 2005, 106, 904-904.	1.4	0
212	SAFETY of PROTHROMBIN COMPLEX CONCENTRATES IN PATIENTS REQUIRING RAPID REVERSAL of ANTICOAGULANT TREATMENT with the VITAMIN K ANTAGONISTS: a Systematic Review and a Meta-Analysis of the Literature Blood, 2010, 116, 1113-1113.	1.4	0
213	The Metabolic SYNDROME and the RISK of Venous Thrombosis: RESULTS of AN Individual LEVEL Patient Meta-ANALYSIS. Blood, 2010, 116, 3177-3177.	1.4	0
214	The prophylaxis of venous thromboembolism in medical outpatients: results of a survey among italian general practitioners. Acta Biomedica, 2020, 91, 7-14.	0.3	0
215	Analysis of the characteristics of patients admitted to Internal Medicine wards for exacerbation of chronic obstructive pulmonary disease, and discharge phase optimization. The SDO-ARCA Project of the Scientific Society FADOI. Italian Journal of Medicine, 2020, 14, 156-161.	0.3	0